Kolistimetatnatrium Xellia

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Xellia, is a polymyxin antibiotic presented as an injectable solution for intravenous use. It treats serious infections caused by susceptible Gram‑negative bacteria, including Pseudomonas aeruginosa, in hospitalised patients. GNH USA supplies Kolistimetatnatrium Xellia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kolistimetatnatrium Xellia is a polymyxin antibiotic used to treat severe Gram‑negative bacterial infections.

Pseudomonas aeruginosa infections: effective against serious infections caused by susceptible strains. Other Gram‑negative bacterial infections: used for life‑threatening infections caused by susceptible organisms. Ventilator‑associated pneumonia: employed when caused by susceptible Gram‑negative pathogens.

Adverse reactions may occur with colistimethate sodium therapy.

Common Side Effects: - Nephrotoxicity: increased serum creatinine and reduced renal function. - Neurotoxicity: paresthesia, dizziness, or peripheral neuropathy. - Rash or mild skin reactions. - Nausea or vomiting. - Fever or chills.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate intervention. - Respiratory distress or bronchospasm. - Seizures or convulsions. - Neuromuscular blockade leading to respiratory failure. - Severe electrolyte disturbances.

Colistimethate sodium requires careful monitoring in several clinical situations.

Renal impairment: adjust dosing and monitor renal function closely. Neuromuscular disease: avoid or use with caution due to risk of blockade. Concomitant nephrotoxic drugs: avoid combination to reduce kidney toxicity. Pregnancy and lactation: safety not established; weigh benefits against risks. Therapeutic drug monitoring: consider measuring serum levels in prolonged therapy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Colistimethate sodium may interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: increased risk of renal impairment. - Neuromuscular blocking agents: enhanced neurotoxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential renal function decline. - Vancomycin: combined renal toxicity risk. - Other nephrotoxic antibiotics: monitor kidney parameters.